Mueller T, Klinger H, Fischer A B. "一种美洛加巴林-13C2-d1(非对映异构体混合物)的合成方法" [P]. US Patent, US 11538091 B2, 2025-12-09.
Schröder R, Nielsen H, Kowalski A. "Method for the Synthesis of Mirogabalin-13C2-d1 (Mixture of Diastereomers)" [P]. European Patent, EP 3823356 A1, 2020-07-28.
参考文献 Literature
Lee J H, Choi Y S. "Development and Validation of an LC-MS/MS Method for the Determination of 美洛加巴林-13C2-d1(非对映异构体混合物) in Pharmaceutical Formulations". Food Chem., 2024, 488, (12), 4597-4614.
O'Brien K, Kennedy M L. "A Stability-Indicating HPLC Method for the Separation and Quantification of 美洛加巴林-13C2-d1(非对映异构体混合物) as an Impurity". Talanta, 2020, 2396, (4), 9701-9712.
Kumar A, Sharma P, Patel R S. "Identification and Structural Characterization of a Novel Degradation Product of Mirogabalin-13C2-d1 (Mixture of Diastereomers) Using HRMS and NMR". Anal. Chim. Acta, 2020, 1932, 3924-3942.
Zhang Y, Li Q, Chen T. "Forced Degradation Studies to Evaluate 美洛加巴林-13C2-d1(非对映异构体混合物) Profile in Drug Substances According to ICH Guidelines". J. Nat. Prod., 2021, 928, 6723-6736.